M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Pharmaceutical TechnologyThe funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.M&A / DealsOncologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Technology The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Activist investor renews its criticism of NovavaxNext: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
